Full history for every metric is available with a Kvantra account
Key financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CHF m | 219 | 252 | 319 | 326 | 385 | 428 | 428 | 468 |
| Operating profit | CHF m | 117 | 112 | ||||||
| Net profit | CHF m | 52 | 59 | 88 | 81 | 106 | 104 | 104 | 108 |
| EPS reported | CHF | 7.49 | 7.50 | ||||||
| Operating cashflow per share | CHF | 8.29 | 8.22 | ||||||
| Capex per share | CHF | 6.17 | 6.10 | ||||||
| FCF per share | CHF | 2.12 | 2.12 | ||||||
| Free cash flow | CHF m | 29.3 | 29.3 | ||||||
| Net debt | CHF m | -70.0 | -70.0 | ||||||
| Book value equity | CHF m | 1,097 | 1,097 | ||||||
| Book value per share | CHF | 79.34 | 79.34 | ||||||
| Number of shares | m | 13.82 | 13.82 | ||||||
| DPS (TTM paid) | CHF | 0.00 | 0.00 |
Financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 45.86 | - | ||||||
| P/B LTM | x | 4.33 | 3.30 | ||||||
| P/S LTM | x | 11.08 | 8.44 | ||||||
| P/FCF LTM | x | 162.10 | 123.48 | ||||||
| EV/EBITDA LTM | x | 31.57 | 24.65 | ||||||
| EV/Sales LTM | x | 11.11 | 8.27 | ||||||
| Earnings Yield LTM | % | 2.18% | 2.87% | ||||||
| FCF Yield | % | 0.62% | 0.81% | ||||||
| Quality | |||||||||
| ROE | % | 9.45% | 9.70% | ||||||
| ROIC | % | 8.13% | 7.79% | ||||||
| Operating margin | % | 27.35% | 26.19% | ||||||
| Gross margin | % | 63.63% | 32.23% | ||||||
| FCF/Sales | % | 6.84% | 6.83% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -1.96% | -1.96% | ||||||
| Sales Growth YoY | % | +11.22% | +11.22% | ||||||
| Net Income Growth YoY | % | -1.87% | -1.87% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | -1.06% | -1.06% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.23 | 0.23 | ||||||
| Net Debt/EBITDA | x | 0.07 | 0.07 | ||||||
| EBIT/Net interest | x | 83.39 | 68.85 | ||||||
| Net debt/market cap | % | -1.48% | -1.94% | ||||||
| Net debt/Equity | x | -0.06 | -0.06 | ||||||
| Gross debt/equity | x | 0.12 | 0.12 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Dottikon ES Holding AG manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical maceutic industries in Europe, Switzerland, the United States, and Asia. The company’s chemicals and intermediates include amines, anilines, azaindoles, benzimidazoles, benzoic acid derivatives, benzyl compounds, boron building blocks, chiral compounds, cyclohexane derivatives, cyclopropyl building blocks, indazoles, indoles, N-heterocycles, nitrate esters, nitroaromatic compounds, O-heterocycles, phenols and anisoles, and pyridine building blocks. It also offers Dottisol, an isosorbide dimethyl ether for application as a solubility enhancer in cosmetic, pharma, and agro products, as well as a performance additive in various industries. In addition, the company is involved in recycling and waste treatment which includes the recycling, thermal recovery, and high-temperature incineration of waste streams, as well as wastewater treatment and purification activities. Further, it offers chemical custom manufacturing, nitrosamine risk assessment, and containment services; and performance chemicals, including aromatic and alicyclic diamines, bio-based organosilanes, and phlegmatized azides. The company was founded in 1913 and is headquartered in Dottikon, Switzerland. Dottikon ES Holding AG is a subsidiary of EVOLMA Holding AG.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Dottikon ES Holding AG (DESN.SW)
Based on consensus from external analysts. Not Kvantra's opinion.
Dottikon ES Holding AG manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical maceutic industries in Europe, Switzerland, the United States, and Asia. The company’s chemicals and intermediates include amines, anilines, azaindoles, benzimidazoles, benzoic acid derivatives, benzyl compounds, boron building blocks, chiral compounds, cyclohexane derivatives, cyclopropyl building blocks, indazoles, indoles, N-heterocycles, nitrate esters, nitroaromatic compounds, O-heterocycles, phenols and anisoles, and pyridine building blocks. It also offers Dottisol, an isosorbide dimethyl ether for application as a solubility enhancer in cosmetic, pharma, and agro products, as well as a performance additive in various industries. In addition, the company is involved in recycling and waste treatment which includes the recycling, thermal recovery, and high-temperature incineration of waste streams, as well as wastewater treatment and purification activities. Further, it offers chemical custom manufacturing, nitrosamine risk assessment, and containment services; and performance chemicals, including aromatic and alicyclic diamines, bio-based organosilanes, and phlegmatized azides. The company was founded in 1913 and is headquartered in Dottikon, Switzerland. Dottikon ES Holding AG is a subsidiary of EVOLMA Holding AG.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free